↓ Skip to main content

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Overview of attention for article published in The Lancet, October 2014
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news
7 news outlets
blogs
3 blogs
policy
1 policy source
twitter
16 X users
patent
18 patents
facebook
1 Facebook page

Citations

dimensions_citation
634 Dimensions

Readers on

mendeley
484 Mendeley